Response to letter – Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists

androgen deprivation therapy and cardiovascular risk

Androgen Deprivation Therapy and Cardiovascular Risk

PURPOSE The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality. PATIENTS AND METHODS A total of 7,248 men in the CaPSURE registry were analyzed. Treatment was categori...

Cardiovascular risk associated with androgen deprivation therapy.

Prostate cancer is the second leading cause of cancer-related death among men in the United States.[1] Androgen deprivation therapy (ADT) is a common treatment for prostate cancer. ADT includes gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin), bilateral orchiectomy, and anti-androgen receptor blockers such as flutamide and bicalutamide. Several studies have no...

Cardiovascular risks of androgen deprivation therapy.

Prostate adenocarcinoma is the most common cancer type in the male sex after skin cancer. Among the several types of treatment for prostate cancer, the androgen deprivation therapy has been highly recommended in patients with metastatic or locally advanced disease, which probably results in increased survival. However, the androgen deprivation is the cause of several adverse effects. Complicati...

Androgen Deprivation Therapy–Induced Cardiovascular Disease

Why did the patients who underwent orchidectomy have statistically significantly higher prostatespecific antigen? It would have been informative if we had the baseline glucose, lipid profile, and indices of obesity for patients receiving ADT to show that their cardiovascular risk factors definitely increased with ADT. As there is a definite increase in cardiovascular risk factors with ADT, we s...